首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 546 毫秒
1.
试验将替米考星以高、中、低(400 mg/kg、200 mg/kg1、00 mg/kg饲料)三个剂量和土霉素以600 mg/kg拌入饲料中饲喂仔猪15 d,称重结果,替米考星高、中、低三个剂量组及土霉素组与对照组相比均有明显的增重效果(P<0.01),尤其是替米考星高剂量组的增重效果显著高于替米考星中、低剂量组及土霉素组(P<0.01),增重效果与替米考星在饲料中的添加剂量成正比。人工感染试验结果:替米考星及土霉素拌料给药对预防猪胸膜肺炎放线杆菌病均有明显的效果,可降低发病率和死亡率,提高成活率,减少病理损害,降低人工感染对增重的影响,尤其以替米考星高、中剂量组预防效果最佳,效果明显优于土霉素组(P<0.01)。用于预防感染,临床推荐剂量为200mg/kg饲料拌料,连续饲喂15 d左右。  相似文献   

2.
2月龄猪试验感染胸膜肺炎放线杆菌血清2型菌株,于感染后第3天起用不同剂量替米考星预混剂和泰乐菌素预混剂混饲治疗。结果表明,替米考星100mg/kg和泰乐菌素500mg/kg虽然均可显著(P<0.05)减轻胸膜肺炎放线杆菌感染猪的临床症状和肺组织损伤,但替米考星200mg/kg和400mg/kg治疗组只有个别猪出现轻微的临床症状和肺组织损伤,认为替米考星预混剂200~400mg/kg混饲可有效治疗猪传染性胸膜肺炎。  相似文献   

3.
摘要:本试验将替米考星注射剂以高、中、低(15mg/kg、 10mg/kg、5mg/kg体重)三个剂量, 1次/d和头孢唑林钠以25mg/kg体重, 2次/d,皮下注射治疗猪传染性胸膜肺炎,均连用3d,停药。结果表明,替米考星注射剂三个剂量组和头孢唑林钠对照组对猪传染性胸膜肺炎均有明显的治疗效果,成活率可达70%-100%,极显著的高于感染对照组(P<0.01)。尤其是替米考星低剂量组成活率显著高于替米考星高、中剂量组及头孢唑林钠组 (P<0.01)。增重效果统计结果表明,替米考星高、中、低三个剂量组与药物对照组及健康对照组之间增重效果无明显差异 (P>0.05)。本试验表明,替米考星能减少人工感染引起的临床症状、降低死亡率和提高日增重。作为注射剂治疗急性猪胸膜肺炎放线杆菌感染,以剂量(5mg/kg体重)为佳。 关键词:替米考星,头孢唑林钠,仔猪,胸膜肺炎放线杆菌  相似文献   

4.
本试验利用人工诱发猪气喘病的动物模型,设计高、中、低剂量(剂量分别为400、200、100mg/kg饲料)的替米考星治疗试验组和阳性对照组(不用药、强毒感染)、阴性对照组(不用药不感染),通过观察、检测试验猪在试验前后的增重变化和试验治疗后肺部病变率来判定替米考星的治疗效果。结果成功建立了人工诱发的猪气喘病模型,替米考星高、中剂量组的治疗效果显著,在增重和肺部病变率方面和阴性对照组差异不显著(P>0.05),而替米考星低剂量组的治疗效果略差,在增重方面和阴性对照组差异不显著(P>0.05),但在肺部病变率方面和阴性对照组差异显著(P<0.05)。这些结果为临床合理地使用替米考星防治猪气喘病提供了科学依据。  相似文献   

5.
为了评价磷酸替米考星对仔猪自然感染肺炎支原体的治疗效果,选取支原体肺炎患猪,10%磷酸替米考星可溶性粉混饮给药,每日1次,连用7 d,通过检测各组受试猪死亡率、治愈率、有效率、增重效果、感染仔猪的肺部病变评分等指标对受试药物的临床治疗效果进行研究。结果显示:10%磷酸替米考星可溶性粉80 mg/L剂量组治愈率最佳,与其他2个药物治疗组相比差异显著(P0.05);药物治疗有效率10%磷酸替米考星可溶性粉80 mg/L剂量组最高,但3个药物治疗组之间差异不显著(P0.05);10%磷酸替米考星可溶性粉60~80 mg/L能有效改善猪群相对增重率(P0.05),但仍显著低于健康猪群(P0.05);10%磷酸替米考星可溶性粉60~80 mg/L剂量组、10%替米考星可溶性粉组均可明显降低病猪肺脏病变评分(P0.05)。结果表明:60~80 mg/L剂量的10%磷酸替米考星可溶性粉饮水治疗猪自然感染肺炎支原体的效果显著,且治疗效果与10%替米考星可溶性粉相当。  相似文献   

6.
为了解替米考星纳米乳对鸡毒支原体病的治疗效果,采用替米考星纳米乳(以替米考星计)高(100 mg/L)、中(75 mg/L)、低(50 mg/L)剂量饮水治疗人工感染鸡毒支原体S6菌株的肉仔鸡,同时设替米考星溶液(100 mL∶10 g)高、中、低剂量组和阳性、阴性对照组,连续给药5 d。结果表明,替米考星纳米乳各剂量组对鸡毒支原体病的治疗效果均优于替米考星溶液相应剂量组;替米考星纳米乳高、中剂量组的适口性优于替米考星溶液。研究为替米考星纳米乳在兽医临床上的应用提供理论依据。  相似文献   

7.
将替米考星以高、中、低(300、200、100mg/L)3个剂量和泰乐菌素以500mg/L饮水给药5d,治疗仔鸡人工感染禽巴氏杆菌病,结果表明,2种药物对治疗该病均有一定的效果,替米考星3个剂量组和泰乐菌素组的有效率均极显著高于感染对照组(P<0.01)。替米考星3个剂量组的有效率均极显著高于泰乐菌素组(P<0.01)。替米考星高、中剂量组有效率极显著高于低剂量组(P<0.01)。而替米考星高、中剂量组间的死亡率、有效率均无统计学差异(P>0.05)。  相似文献   

8.
为评价头孢噻呋混悬剂对猪胸膜肺炎放线杆菌病的疗效,本试验通过小鼠人工感染猪胸膜肺炎放线杆菌建模,用不同剂量的头孢噻呋混悬剂(2、5、10mg/kg)进行临床疗效试验,并用头孢噻呋钠注射剂作为对照,结果5mg/kg和10mg/kg组治愈率均为100%,且头孢噻呋混悬剂较头孢噻呋注射剂效果更佳。因此,头孢噻呋混悬剂以5mg/kg剂量治疗小鼠放线杆菌病效果显著。  相似文献   

9.
肉仔鸡人工感染霉形体S6株后,用替米考星溶液(以替米考星计)50mg/L、100mg/L、200mg/L进行饮水治疗,同时设酒石酸泰乐菌素可溶性粉饮水对照组,于感染后第2天起连续用药5d。试验结果表明替米考星溶液100mg/L、200mg/L剂量组效果优于替米考星溶液50mg/L和酒石酸泰乐菌素可溶性粉500mg/L组,替米考星溶液治疗慢性呼吸道病的推荐应用剂量为100mg/L。  相似文献   

10.
本试验在人工感染鸡支原体肺炎模型中,通过受试鸡气囊损伤评分等指标的检测,评估了不同剂量磷酸替米考星可溶性粉对支原体肺炎感染鸡的治疗效果.结果显示,60~ 80 mg/L剂量组10%磷酸替米考星可溶性粉治疗支原体肺炎感染鸡的治愈率和有效率分别可达70%和100%,与目前已经上市销售的10%替米考星可溶性粉(75 mg/L水,以替米考星计)的效果相当,而且由于磷酸替米考星通过增加磷酸基团而显著增加了该药的水溶性,使得该药在临床使用中更加便捷.  相似文献   

11.
OBJECTIVES: To determine the effects of oral administration of tilmicosin in piglets experimentally infected with Actinobacillus pleuropneumoniae. ANIMALS: Forty 3-week-old specific-pathogen free piglets. PROCEDURES: Piglets were assigned to 1 of 4 groups as follows: 1) uninfected sham-treated control piglets; 2) infected untreated piglets that were intratracheally inoculated with 10(7) CFUs of A pleuropneumoniae; 3) infected treated piglets that were intratracheally inoculated with A pleuropneumoniae and received tilmicosin in feed (400 ppm [microg/g]) for 7 days prior to inoculation; or 4) infected treated piglets that were intratracheally inoculated with A pleuropneumoniae and received chlortetracycline (CTC) in feed (1100 ppm [microg/gl) for 7 days prior to inoculation. Bronchoalveolar lavage (BAL) fluid and lung tissue specimens of piglets for each group were evaluated at 3 or 24 hours after inoculation. For each time point, 4 to 6 piglets/group were studied. RESULTS: Feeding of CTC and tilmicosin decreased bacterial load in lungs of infected piglets. Tilmicosin delivered in feed, but not CTC, enhanced apoptosis in porcine BAL fluid leukocytes. This was associated with a decrease in LTB4 concentrations in BAL fluid of tilmicosin-treated piglets, compared with untreated and CTC-treated piglets, and also with a significant decrease in the number of pulmonary lesions. Tilmicosin inhibited infection-induced increases in rectal temperatures, as measured in untreated and CTC-treated piglets. Pulmonary neutrophil infiltration and prostaglandin E2 concentrations in the BAL fluid were not significantly different among groups at any time. CONCLUSIONS AND CLINICAL RELEVANCE: Oral administration of tilmicosin to infected piglets induces apoptosis in BAL fluid leukocytes and decreases BAL fluid LTB4 concentrations and inflammatory lung lesions.  相似文献   

12.
通过鲎素抗菌肽和超高静水压联合作用,制备出一种胸膜肺炎放线杆菌菌影。利用胸膜肺炎放线杆菌血清5型(CVCC263)制备菌影并检测其灭活率。CVCC263菌影疫苗接种免疫仔猪,二免14d后攻毒,每天测量体温,并观察精神状态,呼吸,食欲等。攻毒第8天对存活猪进行剖杀,测量肺部病变面积,进行病理检测。结果显示,免疫组抗体效价及血清中的IgG、IgM、IgA、IL-2、IL-4含量均较对照组显著增加。免疫组临床症状和肺部病变面积均小于对照组。CVCC263菌影疫苗免疫仔猪抗APP感染的保护效果是明显的,并且APP5型的菌影疫苗可对APP7型感染有交叉保护。  相似文献   

13.
Tilmicosin is a novel macrolide antibiotic developed for exclusive use in veterinary medicine. Tilmicosin has been approved as a feed premix to control porcine respiratory disease associated with Pasteurella multocida and Actinobacillus pleuropneumoniae. The development of antimicrobial susceptibility testing guidelines for tilmicosin was predicated on the relationship of clinical efficacy studies that demonstrated a favorable therapeutic outcome, on pharmacokinetic data, and on in vitro test data, as recommended by the National Committee for Clinical Laboratory Standards (NCCLS). The approved breakpoints for the minimum inhibitory concentration dilution testing for both species are resistant, > or = 32 microg/ml, and susceptible, < or = 16 microg/ml. The zone of inhibition interpretive criteria for disk diffusion testing with a 15-microg tilmicosin disk are resistant, < or = 10 mm, and susceptible, > or = 11 mm.  相似文献   

14.
The aim of this study was to evaluate the efficacy of in-feed medication with tilmicosin phosphate in order to eliminate or reduce the carriage of Actinobacillus pleuropneumoniae in the tonsils of carrier pigs. Two groups of 6 carrier animals received either a non-medicated feed (control group) or feed medicated with 400 ppm of tilmicosin phosphate (treated group) for 30 d. Three sentinel pigs were then introduced in each group and left for 29 d. The presence of A. pleuropneumoniae in tonsils was monitored using several techniques, including polymerase chain reaction (PCR). At the end of the treatment all of the control animals, but only 1 treated pig, were positive by PCR from tonsillar surface material. However, at necropsy, all control and most treated animals, as well as 1 sentinel animal, in both groups were positive by PCR from whole tonsils. In conclusion, under the experimental conditions, in-feed treatment with 400 ppm of tilmicosin phosphate significantly reduced the presence of A. pleuropneumoniae on the surface of tonsils but was unable to completely eliminate the organism from deeper tonsillar tissues and to prevent bacterial shedding by carrier animals.  相似文献   

15.
The authors have performed a comparative study of the efficacy of various in-feed medications for the treatment of 5- to 6-week-old specific pathogen-free (SPF) piglets experimentally infected on day 1 with Mycoplasma hyopneumoniae, on day 8 with Pasteurella multocida (serotype A), and on day 15 with Actinobacillus pleuropneumoniae (serotype 2). The treatment started on day 9 and continued for 12 consecutive days, then the piglets were euthanized for examination of macroscopic, histologic, and pathologic lesions and for the presence of mycoplasmas and bacteria in the lungs. Based on the results of clinical observations (respiratory signs, rectal temperature, body weight gain, and feed conversion efficiency), macroscopic and histologic lesions of the lungs, and microbiologic findings, the best results were obtained by treatment of pigs with Econor + chlortetracycline, followed by Tetramutin, Pulmotil, Cyfac, and lincomycin + chlortetracycline.  相似文献   

16.
The objectives of the present study was to describe different dynamics of humoral immune responses to experimental infection in piglets of different stages of infection and immunity. Two groups of piglets originating from non-immune (group 1) and immune (group 2) sows at the age of 3 weeks were subdivided as follows: a half of each group of piglets was exposed to a low-dose infection with Actinobacillus pleuropneumoniae (APP) strain 9. At the age of 8 weeks, all four groups of piglets were challenged with a high infection dose of APP of the same strain. Isotype characterization of the specific antibodies in sera and in bronchoalveolar lavage fluids (BALF) to a lipopolysaccharide was carried out, besides monitoring clinical signs and post-mortem examinations. A typical primary immune response was observed in specific antibody-free piglets infected with a challenge infection. Colostrum-derived immunoglobulin-G (IgG) antibodies persisted in sera and BALF of piglets up to the age of 8 weeks. However, they did not prevent induction of specific-primary antibody response, either in 8 or 4 weeks of age, when levels of specific colostrum-derived antibodies were still high. It was demonstrated by the increase of specific IgM antibodies in sera. The infection induced an increase in the levels of IgA antibodies in BALF regardless the severity of infection and presence of specific colostrum-derived antibodies. The specific antibodies of IgG isotype increased only in BALF from piglets without colostrum-derived antibodies.  相似文献   

17.
SPF pigs aged 10 weeks were infected intranasally with Actinobacillus pleuropneumoniae serotype 2. After the onset of clinical symptoms of respiratory disease, which occurred 20 h post-infection, parenteral treatment with ceftiofur, danofloxacin, enrofloxacin, penicillin or tiamulin was initiated (n = 8 per group). Untreated groups, of which one was infected, served as controls. The uninfected control group did not show any signs of disease, while the infected control group was severely affected by the infection and also expressed a decreased weight gain following the challenge. Based on clinical signs, the magnitude of pathological lesions in the respiratory tract found at necropsy performed 17 days post-infection and the number of reisolates of A. pleuropneumoniae made at necropsy, treatments with the quinolones (danofloxacin and enrofloxacin) and the cephalosporine (ceftiofur) were superior to those with penicillin and tiamulin. The latter groups also developed antibodies to A. pleuropneumoniae to a larger extent. Some of the pigs treated with ceftiofur and danofloxacin developed antibodies to A. pleuropneumoniae, and the microbe was reisolated from approximately 50% of these animals. In contrast, pigs treated with enrofloxacin did not develop antibodies to A. pleuropneumoniae, and the challenge strain was not found at necropsy. The performance with respect to daily weight gain and feed conversion corresponded well with the clinical signs developed and the findings made at necropsy. The decreased growth recorded during the acute phase of the disease was, to a large extent, caused by a reduced feed intake.  相似文献   

18.
The effectiveness of medication with doxycycline in feed in the control of pleuropneumonia in pigs was tested using an Actinobacillus pleuropneumoniae serotype 1 aerosol challenge model. Two groups of 10 animals were used for the challenge, a 'medicated group' and an 'unmedicated group'. A third group of four animals was used as a 'control group'. Pigs from the medicated group were provided with feed containing 250 p.p.m. doxycycline (HIPRAMIX/DOXI) for 8 consecutive days and were challenged on the fifth day of treatment. No clinical signs were observed in pigs from the 'control group'. Four animals from the 'unmedicated group' died within the first 48 h after challenge with clinical and lesional evidence of an acute form of pleuropneumonia. Clinical signs of animals surviving the first 48 h were progressively less severe and showed lesions similar to those described for subacute-chronic forms of the disease. However, only one animal from the 'medicated group' showed clinical signs of a chronic form of pleuropneumonia. Reisolation of A. pleuropneumoniae was more evident from lung tissues of animals fed the doxycycline-free feed (70%), coinciding with the presence of both acute and subacute lesions. However, the micro-organism could be reisolated from only one animal which belonged to the 'medicated group'. It is concluded that the treatment of pigs with 250 p.p.m. doxycycline (HIPRAMIX/DOXI) prevents disease caused by A. pleuropneumoniae.  相似文献   

19.
猪胸膜肺炎调查及地方适用型灭活疫苗的研制   总被引:1,自引:0,他引:1  
对广东珠江三角洲地区31个猪场450份血清用IHA方法进行猪胸膜肺炎放线杆菌(APP)抗体检查,阳性猪场和阳性血清分别为96.8%和58.4%;分离鉴定了7株APP,血清分型为1、7、3和4型,且以1、7型毒力较强;用平板凝集法对263份APP抗体阳性血清进行抗体反向分型试验,结果1型、7型共占76.4%。确定了APP最佳液体培养条件,培养菌液CFU为2.4×109/mL;研制的APP 1型、7型二价灭活疫苗安全、稳定。兔和仔猪免疫抗体曲线显示,油乳剂疫苗明显优于铝胶疫苗,二次免疫优于一次免疫;APP双价油乳剂灭活疫苗一次免疫仔猪,能100%抵抗APP同源1、7型强毒菌株的攻击,保护期达110 d;田间试验明显提高猪群的生产成绩。  相似文献   

20.
The virulence of a NAD-independent Actinobacillus pleuropneumoniae serotype 2 strain and NAD-dependent serotype 2, 3 and 9 strains was compared under experimental conditions. Hysterectomy-derived piglets were inoculated endobronchially with 50-500 cfu of these strains. All 23 piglets inoculated with the NAD-dependent strains developed acute disease within 12 hours post inoculation. Twenty-two of these piglets died within 24 hours after the first clinical signs. Three of nine piglets inoculated with the NAD-independent strain did not develop clinical disease. In the other six piglets, disease signs were similar as in the piglets inoculated with the NAD-dependent strains. No differences in clinical disease were observed between colostrum deprived piglets and piglets that obtained colostrum from a SPF sow.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号